​Emergency and Acute Medicine – Lymphangitis
​Basics description
Lymphangitis is an infection of the lymphatic vessels that drain an area of inflammation or infection. Histologically, lymphatic channels become dilated and filled with lymphocytes and histiocytes. Inflammation often extends into surrounding perilymphatic tissues and may progress to cellulitis or abscess formation if untreated.
Etiology
Acute lymphangitis is most commonly caused by bacterial infection, particularly group A β-hemolytic Streptococcus. Less common causes include other streptococcal species and Staphylococcus aureus, including community-associated methicillin-resistant S. aureus (CA-MRSA). CA-MRSA risk factors include prior MRSA infection, close household contact, military service, incarceration, contact sports, injection drug use, and men who have sex with men. CA-MRSA is now prevalent enough to warrant empiric coverage in many settings, especially in unresponsive or recurrent infections. Other causes include Pasteurella multocida from animal bites, Spirillum minus in rat-bite fever, and Wuchereria bancrofti in filariasis, particularly in immigrants from endemic regions. Chronic lymphangitis is usually due to fungal, mycobacterial, or parasitic infections, most commonly Sporothrix schenckii, acquired through gardening or farming injuries, and Mycobacterium marinum, associated with fish tanks and swimming pools.
Diagnosis signs and symptoms
Acute lymphangitis presents with warm, tender, erythematous streaks extending proximally from a primary site of infection toward regional lymph nodes. Associated findings include painful lymphadenopathy, peripheral edema of the involved extremity, and systemic symptoms such as fever, rigors, tachycardia, and headache. Chronic nodular lymphangitis typically presents with painless erythematous nodules, chancriform ulcers, or wart-like lesions at the inoculation site, with possible progression along lymphatic channels and minimal systemic symptoms.
Essential workup
Lymphangitis is primarily a clinical diagnosis based on history and physical examination, with attention directed toward identifying the source of infection.
Diagnosis tests and interpretation
Laboratory testing is often unnecessary, though leukocytosis may be present. Gram stain and culture of aspirate or biopsy from the most inflamed area are recommended in cases of treatment failure or when resistant organisms such as MRSA are suspected. Culture confirmation is essential when sporotrichosis or M. marinum infection is considered. Blood cultures may be positive in severe cases. Imaging is rarely required but plain radiographs may help identify abscesses, subcutaneous gas, or foreign bodies, and Doppler ultrasound may be useful to exclude deep venous thrombosis.
Differential diagnosis
The differential diagnosis includes superficial or deep thrombophlebitis, which typically lacks an initial infectious focus or regional lymphadenopathy, IV line infiltration, vaccine-related reactions, and phytophotodermatitis, which can cause linear inflammatory skin changes mimicking lymphangitis.
Treatment
Initial management focuses on stabilizing septic patients with airway support and resuscitation as needed. Antimicrobial therapy should be initiated promptly, with the first dose given in the emergency department. Treatment typically lasts 7–10 days and includes limb elevation, moist heat, and antibiotics guided by local resistance patterns. Empiric outpatient therapy often includes oral cephalexin plus trimethoprim–sulfamethoxazole to cover CA-MRSA, with alternatives such as clindamycin or doxycycline. Inpatient therapy may require IV nafcillin or equivalent agents. Animal bite–associated lymphangitis is treated with IV ampicillin–sulbactam. Chronic infections require organism-specific therapy, such as itraconazole or potassium iodide for sporotrichosis and combination antimycobacterial therapy for M. marinum.
Disposition and follow-up
Admission is indicated for toxic-appearing patients, those with immunosuppression, significant comorbidities, inability to tolerate oral therapy, or unreliable follow-up. Patients with mild disease who are clinically stable and able to take oral antibiotics may be discharged with close follow-up within 24–48 hours. Marking the borders of erythema before discharge helps assess treatment response.
Pearls and pitfalls
Empiric antibiotic therapy should include coverage for CA-MRSA in addition to streptococcal species. Failure to recognize resistant organisms or chronic infectious causes can lead to treatment failure and progression of disease.

Emergency and Acute Medicine – Malaria
Basics description
Malaria is a protozoan infection transmitted through the bite of an infected female Anopheles mosquito. The incubation period is typically 8–16 days, although symptoms may be delayed for months depending on the species. The periodic nature of malaria symptoms reflects the parasite life cycle, which includes an exoerythrocytic phase in the liver followed by an erythrocytic phase in red blood cells. Fever corresponds to synchronous red blood cell lysis and release of merozoites into the circulation.
Pathophysiology and species differences
In the exoerythrocytic phase, sporozoites migrate to the liver and multiply into merozoites. These then enter the bloodstream and invade red blood cells, where replication leads to cell rupture every 48–72 hours. Plasmodium falciparum causes most severe disease and nearly all malaria-related deaths. It infects red blood cells of all ages, leading to profound hemolysis, anemia, and capillary obstruction with resultant end-organ hypoxia. Plasmodium vivax and Plasmodium ovale may cause relapsing disease due to dormant liver forms (hypnozoites), while Plasmodium malariae can persist at low levels in the bloodstream for decades.
Etiology and transmission
Transmission usually occurs via mosquito bite but may also result from blood transfusions or shared needles. Rare autochthonous transmission has been reported in North America due to the presence of Anopheles mosquitoes. Post-traumatic immunosuppression may precipitate relapse in individuals previously exposed in endemic regions. Children with sickle cell trait have partial protection, while pregnant patients—especially primigravidas—are at higher risk for severe disease.
Diagnosis signs and symptoms
Most patients become symptomatic within one year of exposure. Common symptoms include malaise, chills, fever greater than 38°C, myalgias, arthralgias, and orthostatic hypotension. The classic malaria paroxysm consists of chills followed by high fever and subsequent diaphoresis, although this pattern is uncommon in clinical practice. Hemolysis may lead to jaundice, dark urine (blackwater fever), anemia, and splenomegaly. Severe manifestations include cerebral malaria with headache, altered mental status, seizures, or coma; pulmonary edema; renal failure; abnormal bleeding; and circulatory collapse.
Essential workup and diagnostic testing
Diagnosis relies on oil immersion light microscopy of thick and thin Giemsa-stained blood smears, which demonstrate intraerythrocytic parasites. At least three negative smears over 48 hours are required to exclude malaria. Laboratory findings commonly include anemia, thrombocytopenia, leukocytopenia, elevated bilirubin and lactate dehydrogenase, electrolyte abnormalities, and evidence of renal or hepatic dysfunction. Chest radiography may reveal pulmonary edema. Advanced testing such as antigen detection assays or PCR can identify Plasmodium species and mixed infections. Lumbar puncture may be necessary to distinguish cerebral malaria from meningitis.
Differential diagnosis
The differential includes meningitis, encephalitis, sepsis, acute renal failure, viral hepatitis, acute hemolytic anemia, hypoglycemic coma, and heat stroke. In travelers or immigrants from endemic areas, malaria must be considered in any febrile illness.
Treatment and emergency management
Initial stabilization includes airway, breathing, and circulation management, isotonic fluid resuscitation for hypotension, active cooling for hyperthermia, and treatment of hypoglycemia or seizures as indicated. Antimalarial therapy depends on species, severity, and geographic resistance patterns, with artemisinin-based combination therapies recommended as first-line treatment worldwide. Severe P. falciparum infection requires intravenous artesunate. Supportive care for complications such as anemia, renal failure, and cerebral edema is critical.
Disposition and follow-up
ICU admission is indicated for severe P. falciparum malaria, high parasitemia, neurologic involvement, or inability to tolerate oral therapy. Patients with non–P. falciparum malaria who are clinically stable and able to take oral medications may be treated as outpatients with close follow-up.
Pearls and pitfalls
Malaria should always be considered in patients with fever and compatible exposure history, even months after travel. Fever patterns are unreliable, and early recognition is essential, as delays in treatment—especially with P. falciparum—are associated with high mortality.

​Emergency and Acute Medicine – Mallory–Weiss Syndrome
​Basics description
Mallory–Weiss syndrome is a partial-thickness, longitudinal mucosal tear of the distal esophagus or proximal stomach. It results from a sudden increase in intra-abdominal or transgastric pressure, leading to mild to moderate submucosal arterial or venous bleeding. Endoscopic observations suggest that transient “mushrooming” of the stomach into the esophagus during forceful retching contributes to tear formation. It accounts for approximately 5% of all cases of upper gastrointestinal bleeding.
Etiology and risk factors
The condition is most commonly associated with forceful vomiting or retching but may also occur with coughing, laughing, lifting, straining, blunt abdominal trauma, seizures, childbirth, or cardiopulmonary resuscitation. Alcohol use, particularly following binge drinking, and the presence of a hiatal hernia are significant risk factors. More severe bleeding is seen in patients with portal hypertension, esophageal varices, or underlying coagulopathy.
Diagnosis signs and symptoms
Patients typically report multiple episodes of nonbloody vomiting or retching followed by hematemesis. Most bleeding is self-limited, though severe or life-threatening hemorrhage can occur. Associated symptoms include epigastric or back pain and signs of volume depletion such as dizziness, light-headedness, or syncope. Physical examination may reveal hematemesis, melena, postural hypotension, or shock in severe cases.
Essential workup and diagnostic testing
Initial evaluation includes a complete blood count and rectal examination for occult blood. Additional laboratory studies include coagulation parameters, electrolytes, renal function tests, liver function tests, and type and cross-match if bleeding is significant. Upright chest radiography may be obtained to exclude esophageal or gastric perforation. Upper endoscopy is the diagnostic and therapeutic modality of choice, allowing direct visualization and management of the bleeding source.
Differential diagnosis
Conditions to consider include nasopharyngeal bleeding, hemoptysis, esophageal rupture (Boerhaave syndrome), esophagitis, gastritis, peptic ulcer disease, variceal bleeding, malignancy, and vascular-enteric fistula.
Treatment and emergency management
Initial management focuses on airway protection, oxygenation, and hemodynamic stabilization with large-bore intravenous access and fluid resuscitation. Blood transfusion is indicated for ongoing bleeding or hemodynamic instability. Most cases resolve with conservative therapy. Persistent or active bleeding requires urgent endoscopic intervention, which may include injection therapy, thermal coagulation, clipping, or band ligation. Proton pump inhibitors and antiemetics are used adjunctively. Surgical or angiographic intervention is reserved for refractory cases.
Disposition and follow-up
Patients with ongoing or massive hemorrhage, hemodynamic instability, significant comorbidities, or advanced age require ICU admission. Stable patients with minimal bleeding that has resolved and stable hematocrit may be admitted for observation or, in select cases, discharged with close follow-up and outpatient endoscopy.
Key points and cautions
Early placement of large-bore intravenous access and prompt resuscitation are critical in upper gastrointestinal bleeding. Early gastroenterology consultation is essential when bleeding is significant. Rebleeding most often occurs within the first 24 hours and is more likely in patients with coagulopathy or portal hypertension.

KembaraXtra-Medicine – Autoimmune Hemolytic Anemia


Autoimmune hemolytic anemia (AIHA) is a condition in which autoantibodies and/or complement bind to red blood cells (RBCs), leading to their premature destruction. About half of cases are primary (idiopathic), while the rest are secondary to underlying diseases or drugs. AIHA is commonly categorized into warm antibody–mediated disease (usually IgG, reacting best at 37°C), cold antibody–mediated disease (typically IgM with complement), and drug-induced immune hemolysis.


AIHA is uncommon, with an annual incidence of about 1 to 3 cases per 100,000 people and an estimated mortality around 10%. It is reported more often in women younger than 50 years. Patients most commonly present with fatigue and dyspnea. Pallor and jaundice may be present, and tachycardia with a flow murmur can occur when anemia is significant. Intravascular hemolysis may cause dark urine and back pain. Hepatomegaly or lymphadenopathy suggests a lymphoproliferative disorder or malignancy, while splenomegaly may suggest hypersplenism. The course is often chronic with relapses.


Warm AIHA is usually mediated by IgG antibodies and may be idiopathic or associated with leukemia/lymphoma, thymoma, myeloma, viral infections, babesiosis, and collagen-vascular diseases. Cold AIHA is commonly IgM- and complement-mediated and may be idiopathic or linked to infections, lymphoma, or cold agglutinin disease. Drug-induced AIHA can occur through different immune mechanisms, including antibodies directed against RBC antigens (e.g., methyldopa), antibodies against an RBC–drug complex (hapten type, e.g., penicillin), or immune complex mechanisms (e.g., quinidine).


The differential diagnosis includes non-immune causes of hemolysis such as microangiopathic hemolytic anemia (e.g., TTP/HUS), hypersplenism, prosthetic valve hemolysis, infections, toxins, and inherited causes such as membrane disorders (e.g., hereditary spherocytosis), hemoglobinopathies, and enzyme deficiencies (e.g., G6PD). Chronic lymphocytic leukemia (CLL) can cause a positive direct antiglobulin test (DAT) without true AIHA, so labs and clinical evidence of hemolysis are important.


Evaluation focuses on confirming hemolysis and establishing immune causation. Typical hemolysis findings include reticulocytosis (or reticulocytopenia if marrow suppression is present), low haptoglobin, elevated indirect bilirubin, and elevated LDH. Initial tests include CBC, reticulocyte count, bilirubin/LDH, and a peripheral smear (spherocytes are typical in warm AIHA). The key diagnostic test is the direct antiglobulin test (DAT/Coombs), performed initially with a polyspecific reagent to detect IgG and/or complement on RBCs. A positive DAT supports AIHA: IgG ± C3d suggests warm AIHA, while C3d alone suggests cold AIHA. Additional evaluation may include hepatitis serologies, HIV testing, ANA, urine testing for hemoglobinuria/hemosiderinuria, and imaging (such as CT chest/abdomen/pelvis) if an underlying lymphoproliferative disorder is suspected.


Management includes stopping any offending drug when drug-induced disease is possible. Severe, life-threatening cases may rarely require plasmapheresis or exchange transfusion. Patients with cold antibody AIHA should avoid cold exposure. Warm AIHA is typically treated first with prednisone 1 to 2 mg/kg/day, with tapering after response. Some evidence supports upfront combination therapy with steroids plus rituximab to improve outcomes and durability of response. For relapse or steroid-refractory disease, rituximab is commonly used and has high response rates, with a substantial portion maintaining remission years later. Splenectomy is now usually reserved for cases refractory to both steroids and rituximab, and further options include immunosuppressive agents such as mycophenolate, cyclosporine, cyclophosphamide, IVIG, and sometimes danazol as an adjunct.


Cold AIHA generally responds poorly to corticosteroids, and treating underlying infection or lymphoproliferative disease is important. In primary cold agglutinin disease, rituximab-based regimens (often with bendamustine in fit patients) are commonly used, while rituximab alone may be used in older or frailer patients. IVIG or plasmapheresis can be used temporarily in severe cases while waiting for a durable therapy to work. Complement-directed therapies may be considered in severe disease; sutimlimab (targeting C1s) has been shown to rapidly reduce hemolysis and improve hemoglobin and fatigue in cold agglutinin disease. Splenectomy is generally ineffective in cold AIHA because clearance occurs mainly in the liver.


Prognosis is generally good unless AIHA is driven by a serious underlying condition such as leukemia or myeloma. Hematology referral is recommended for all AIHA cases, and surgical referral may be needed if splenectomy is being considered for refractory warm AIHA.

KembaraXtra-Medicine – Autoimmune Polyendocrine Syndromes


Autoimmune polyendocrine syndrome (APS) refers to a group of disorders characterized by autoimmune-mediated functional impairment of multiple endocrine glands occurring in specific patterns. These conditions are also known as autoimmune polyglandular syndrome or autoimmune polyglandular failure and include autoimmune polyendocrine syndrome type 1 (APS-1) and type 2 (APS-2). The ICD-10-CM code for autoimmune polyglandular failure is E31.0.


APS-1 may occur at any stage of life but most commonly presents in early childhood or early adulthood. Clinical expression is highly variable, even among family members. Its estimated prevalence is about 1 in 100,000 in most countries, with much higher rates in genetically isolated populations such as Finland, Sardinia, and Persian Jewish communities. APS-2 is more common, with a prevalence ranging from 1 in 1,000 to 1 in 20,000. It predominantly affects women and usually presents between 20 and 40 years of age. Rare cases of APS-2 have been reported following treatment with immune checkpoint inhibitors.


Genetically, APS-1 is most often a monogenic disorder inherited in an autosomal recessive pattern, although autosomal dominant cases have been reported due to dominant-negative mutations of the AIRE gene. APS-2 has a polygenic inheritance pattern with heterogeneous clinical expression resulting from interactions between multiple genetic loci and environmental factors.


APS-1 is defined by the presence of at least two of three major features: hypoparathyroidism, chronic mucocutaneous candidiasis, and primary adrenal insufficiency. Hypoparathyroidism is the most common endocrine manifestation, while chronic mucocutaneous candidiasis is often the first clinical feature to appear. Primary hypogonadism is also common. Other associated features include enamel hypoplasia, bilateral keratitis, autoimmune hepatitis, pneumonitis, nephritis, and functional asplenia. Most patients present by five years of age, with nonendocrine manifestations often preceding endocrine disease. On average, individuals develop four to five associated disorders, with diabetes mellitus usually occurring later in the disease course.


APS-2 is characterized by the triad of autoimmune adrenal insufficiency, autoimmune thyroid disease, and type 1 diabetes mellitus, with adrenal insufficiency required for diagnosis. It typically presents later than APS-1, most often between 20 and 40 years of age. APS-3 differs in that adrenal insufficiency is absent; patients have autoimmune thyroid disease along with other autoimmune conditions such as type 1 diabetes, atrophic gastritis, pernicious anemia, alopecia, vitiligo, or myasthenia gravis.


Individual endocrine disorders present with characteristic clinical features. Hypocalcemia from primary hypoparathyroidism may cause tetany, perioral paresthesias, prolonged QT interval, basal ganglia calcifications, seizures, and arrhythmias. Autoimmune hypothyroidism commonly presents with fatigue, weight gain, constipation, cold intolerance, menstrual irregularities, and hair or nail changes, with myxedema coma representing the most severe manifestation. Autoimmune adrenal insufficiency may present with weight loss, fatigue, nausea, anorexia, malaise, and skin hyperpigmentation, while adrenal crisis can cause hypotension, nausea, and vomiting. Type 1 diabetes mellitus typically presents with polyuria, polydipsia, and weight loss, with diabetic ketoacidosis being the most life-threatening complication. Hypogonadism may manifest as low libido and fatigue in males or oligomenorrhea in females.


The etiology of APS-1 involves inactivating mutations of the autoimmune regulator (AIRE) gene on chromosome 21, leading to defective negative selection of autoreactive T cells and impaired regulatory T-cell function. APS-2 is associated with mutations in the human leukocyte antigen (HLA) complex on chromosome 6, along with other immune regulatory genes, resulting in lymphocytic infiltration and organ-specific autoimmunity.


Diagnosis is often delayed due to the variable and sequential nature of disease manifestations. Rarely do adrenal, thyroid, and pancreatic endocrine disorders develop simultaneously. Once one autoimmune endocrinopathy is identified, regular screening for additional autoimmune conditions is essential. Hypoparathyroidism is diagnosed by low calcium levels with low or inappropriately normal parathyroid hormone levels, after correcting hypomagnesemia if present. Autoimmune hypothyroidism is diagnosed by elevated thyroid-stimulating hormone levels and may be supported by thyroid autoantibodies. Autoimmune adrenal insufficiency is diagnosed by low cortisol levels or inadequate response to cosyntropin stimulation, with elevated ACTH levels and possible electrolyte abnormalities; anti–21-hydroxylase antibodies may be present. Autoimmune hypogonadism is diagnosed by low sex hormone levels with elevated gonadotropins. Type 1 diabetes mellitus is diagnosed by elevated glucose or hemoglobin A1c levels, with diabetes-related autoantibodies often present.


Acute management focuses on life-threatening complications. Chronic mucocutaneous candidiasis requires antifungal therapy, good oral hygiene, and smoking cessation. Severe hypocalcemia is treated with intravenous calcium followed by oral calcium and calcitriol. Myxedema coma requires intravenous thyroid hormone, glucocorticoids, and intensive supportive care. Diabetic ketoacidosis is managed with intravenous fluids, insulin, and electrolyte correction. Suspected adrenal crisis must be treated immediately with intravenous hydrocortisone and volume resuscitation without waiting for laboratory confirmation.


Chronic management centers on lifelong hormone replacement and surveillance for new autoimmune conditions. Hypoparathyroidism is treated with calcitriol and calcium supplementation, with thiazide diuretics used for hypercalciuria and parathyroid hormone replacement reserved for refractory cases. Autoimmune hypothyroidism is treated with oral levothyroxine, ensuring adrenal insufficiency is excluded or treated first. Primary adrenal insufficiency requires glucocorticoid and mineralocorticoid replacement, sick-day education, emergency hydrocortisone access, and medical alert identification. Type 1 diabetes mellitus requires insulin therapy. Primary hypogonadism is treated with sex hormone replacement appropriate to patient anatomy. In APS-1 patients presenting initially with chronic mucocutaneous candidiasis, regular screening for adrenal insufficiency is recommended.


Because disease components accumulate over time, management should be coordinated by a multidisciplinary team led by an endocrinologist. Patient education is essential so individuals can recognize early symptoms of additional autoimmune conditions. APS is frequently diagnosed late due to its heterogeneous presentation, and once one disorder is identified, systematic screening for associated autoimmune diseases should be initiated. All siblings of patients with APS-1 should undergo genetic testing or regular clinical screening, and long-term follow-up is critical for optimizing outcomes.

KembaraXtra-Medicine – Autoimmune Hepatitis


Autoimmune hepatitis (AIH) is an immune-mediated inflammatory liver disease marked by elevated serum gamma globulins (especially IgG), characteristic circulating autoantibodies, and typical biopsy findings of interface hepatitis with plasma cell–rich inflammation, after other causes of hepatitis have been excluded. There are two main types. Type 1 AIH is the most common worldwide (about 90%) and can occur at any age; it is often associated with antinuclear antibodies (ANA) and/or smooth muscle antibodies (SMA), and sometimes anti–soluble liver antigen (anti-SLA) or anti–liver-pancreas (anti-LP) antibodies. Type 2 AIH is less common (up to 10%), mainly affects children and young adolescents, and is typically associated with anti-LKM-1 or anti-LC1 antibodies, while ANA and SMA are usually absent; it often presents more acutely and may be harder to treat, with frequent relapse requiring long-term maintenance therapy.


AIH is more common in females and can occur across all ethnicities and age groups. In the United States, prevalence is estimated around 31 per 100,000 people, and globally incidence is roughly 0.9 to 2 cases per 100,000 people per year, with prevalence estimates ranging widely. Type 1 AIH has a bimodal peak (around puberty and again in mid-to-late adulthood), while type 2 is more common from ages 2 to 14. AIH accounts for a small but important portion of liver transplants in the U.S. (about 4% to 6%).


The exact cause is unknown, but AIH is thought to result from genetic susceptibility plus an environmental trigger. A leading theory involves a T-cell–mediated immune attack on hepatocytes, possibly related to reduced or dysfunctional regulatory T cells; humoral immunity also appears involved given the range of autoantibodies. Proposed triggers include viral infections (hepatitis A, B, C) and medications (such as minocycline, nitrofurantoin, biologics, and TNF inhibitors). Certain HLA haplotypes are associated with increased risk, including HLA-DR3 and DR4 in type 1 AIH and HLA-DR3 and DR7 in type 2.


Clinical presentation is broad, ranging from asymptomatic liver enzyme elevations to cirrhosis or fulminant liver failure. Symptoms may include fatigue, anorexia, nausea, abdominal pain, pruritus, and arthralgias. Some patients have other autoimmune features such as arthritis, dry mouth, eye irritation (keratoconjunctivitis), vasculitis, or erythema nodosum. Advanced disease can present with hepatosplenomegaly, ascites, peripheral edema, easy bruising/bleeding, and jaundice.


Diagnosis is based on a combination of laboratory evidence of liver injury, elevated IgG or hypergammaglobulinemia, characteristic autoantibodies, and compatible liver histology, while excluding other causes of hepatitis. Both major liver societies (EASL and AASLD) require a liver biopsy to establish diagnosis. Histology is suggestive rather than pathognomonic, with findings such as lymphoplasmacytic infiltrates crossing the limiting plate (interface hepatitis), periportal inflammation/necrosis, rosetting of hepatocytes, and emperipolesis. If cholestatic features are present, primary biliary cholangitis and primary sclerosing cholangitis should be evaluated; MRCP is recommended in adults with cholestatic lab changes and in all children with AIH, with ERCP considered if MRCP is nondiagnostic.


Workup includes history and exam (including screening for other autoimmune diseases), liver function tests and serum gamma globulins/IgG, and autoantibody testing (ANA, SMA/ASMA, anti-LKM, anti-SLA/LP). Aminotransferases are usually elevated (often ALT > AST) and may fluctuate; bilirubin and alkaline phosphatase may be normal or moderately elevated. IgG is elevated in about 90% of patients. Ultrasound is commonly used to rule out obstruction or mass, and MRCP is used when cholestasis suggests overlap disease. Patients with AIH-related cirrhosis should undergo hepatocellular carcinoma surveillance (typically ultrasound and AFP every 6 months).


Treatment includes avoiding alcohol and hepatotoxic medications, and considering liver transplantation for fulminant liver failure or end-stage disease. Steroids are the cornerstone: prednisone/prednisolone is commonly started at 0.5 to 1 mg/kg/day (often up to 60 mg/day) for induction. Azathioprine can be started at the same time or about 2 weeks later (often beginning at 50 mg/day and titrating up to 1 to 2 mg/kg/day depending on response and toxicity). In noncirrhotic AIH, budesonide (6 to 9 mg/day) plus azathioprine can be used to induce and maintain remission with fewer systemic steroid side effects; budesonide should not be used in cirrhosis due to reduced first-pass metabolism and increased systemic effects. Steroids may be avoided or used cautiously in brittle diabetes, uncontrolled hypertension, severe osteopenia, psychosis, or prior severe intolerance, while azathioprine is contraindicated in TPMT deficiency and significant cytopenias. Alternatives for azathioprine intolerance include 6-mercaptopurine and mycophenolate mofetil, and other second-line options (e.g., calcineurin inhibitors, sirolimus/everolimus, rituximab, infliximab) have been used in select refractory cases.


Treatment response is monitored with symptoms and normalization of liver tests, but biopsy activity can lag behind lab improvement by up to 6 months. Because relapse is common after withdrawal (often requiring long-term maintenance therapy), repeat biopsy is often considered before stopping therapy. Persistent interface hepatitis on biopsy is associated with very high relapse risk, and multiple relapses are linked with a higher chance of cirrhosis, so repeated attempts at withdrawal are generally discouraged. Acute severe AIH should be treated early with high-dose corticosteroids, and if there is no improvement within about 7 days, urgent transplant evaluation is recommended; acute liver failure presentations should be evaluated directly for transplantation.


Long-term outlook is generally good with treatment: many patients achieve remission within 18 months to 3 years, but a minority do not respond to standard therapy. Patients with decompensated cirrhosis, acute liver failure, hepatocellular carcinoma, or progression despite therapy should be referred for liver transplant evaluation.

KembaraXtra-Medicine – Intestinal Malrotation


Intestinal malrotation is a congenital condition resulting from incomplete rotation and fixation of the intestine during embryogenesis, specifically during the transition from the extracolonic position around the tenth week of gestation. It is commonly associated with heterotaxia syndromes and frequently occurs alongside other congenital anomalies. Gastrointestinal associations include duodenal stenosis or atresia, duodenal web, Meckel diverticulum, intussusception, gastroesophageal reflux, omphalocele, gastroschisis, congenital diaphragmatic hernia, abdominal wall defects, and Hirschsprung disease. Congenital cardiac anomalies are present in approximately 27% of patients and significantly increase morbidity.


The underlying pathology involves abnormal positioning of the duodenojejunal junction, which remains to the right of the midline, and malposition of the cecum, which is often located in the upper left abdomen with abnormal mesenteric attachments. This abnormal anatomy predisposes patients to bowel obstruction and volvulus. Midgut volvulus is a serious complication that occurs when the small intestine twists around the superior mesenteric artery and vein, leading to vascular compromise and potential bowel ischemia. Malrotation is found in combination with other congenital anomalies in up to 70% of cases, particularly involving the cardiac, esophageal, urinary, and anorectal systems.


Malrotation occurs in approximately 1 in 500 live births. It is more common in males, with a male-to-female ratio of 2:1 in neonates. About 75% of cases are diagnosed during the newborn period, and 90% are identified by one year of age, although presentation can occur in adulthood. Mortality in infants can be as high as 24%, and the presence of necrotic bowel at surgery increases mortality risk significantly.


Clinical presentation varies by age. Neonates typically present with bilious vomiting, abdominal distention, bloody stools, constipation or obstipation, feeding difficulties, and poor weight gain. Infants and children older than one year may present with abdominal pain followed by bilious emesis. Older children and adolescents often experience chronic vomiting, intermittent colicky abdominal pain, diarrhea, hematemesis, or constipation. Adults usually present with vague and nonspecific gastrointestinal symptoms. Notably, up to 75% of patients may have a normal physical examination at presentation. Severe cases may show signs of dehydration, metabolic acidosis, peritonitis, ischemic bowel, sepsis, or shock.


Diagnosis is suggested by clinical history and physical examination and is confirmed through imaging, most commonly contrast radiography. Laboratory evaluation includes complete blood count, venous blood gas, electrolytes, renal function tests, glucose, coagulation profile, lactate, and type and screen. Plain abdominal radiographs are diagnostic in fewer than 30% of cases but may show signs suggestive of volvulus, such as duodenal obstruction, gastric distention, paucity of distal bowel gas, generalized small-bowel distention, or a double-bubble sign. Upper gastrointestinal contrast studies are the diagnostic test of choice, with high sensitivity and accuracy, demonstrating abnormal position of the duodenojejunal junction, corkscrew appearance of the duodenum in volvulus, or right-sided jejunum. Contrast enema may help identify cecal position but has a significant false-negative rate. Ultrasound can demonstrate abnormal superior mesenteric artery–vein relationships and the classic whirlpool sign in volvulus, although a normal study does not exclude malrotation. CT imaging is generally reserved for adults.


Differential diagnosis depends on age and presentation. In early life, considerations include Hirschsprung disease, necrotizing enterocolitis, and intussusception. In children with acute abdominal pain and peritoneal signs, appendicitis and sepsis must be considered. Older children and adults with chronic or vague symptoms may be misdiagnosed with irritable bowel syndrome, peptic ulcer disease, biliary or pancreatic disorders, or psychiatric conditions.


Management of malrotation, particularly with midgut volvulus, is a surgical emergency. Initial stabilization focuses on airway, breathing, and circulation, with rapid intravenous fluid resuscitation to correct hypovolemia and metabolic acidosis. Broad-spectrum antibiotics are initiated if there are signs of sepsis or peritonitis. Nasogastric decompression and prompt surgical consultation are essential. Definitive treatment involves emergent surgical correction, including detorsion of the volvulus, restoration of intestinal perfusion, resection of necrotic bowel if present, and reassessment of bowel viability when necessary. Patients are kept nil per os and require close postoperative monitoring.


Hospital admission is indicated for acute abdomen, need for surgical intervention, significant dehydration, acidosis, sepsis, or shock. Discharge is uncommon and reserved for stable, asymptomatic patients with incidental findings after thorough pediatric surgical evaluation. Early recognition, rapid resuscitation, and timely referral to a facility with pediatric surgical expertise are critical to improving outcomes and reducing morbidity and mortality.

KembaraXtra-Medicine – Autosomal Dominant Polycystic Kidney Disease (ADPKD)


Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited form of kidney disease and represents a systemic genetic disorder. It is caused predominantly by sequence variations in the PKD1 and PKD2 genes, which account for approximately 93% of cases. These genetic changes result in progressive formation and enlargement of fluid-filled cysts, mainly in the kidneys, but also in other organs such as the liver and pancreas. In addition to renal involvement, ADPKD is associated with gastrointestinal, connective tissue, and cardiovascular abnormalities.


ADPKD follows an autosomal dominant inheritance pattern, meaning each child of an affected parent has a 50% chance of inheriting the disease. It affects individuals of all ethnic groups worldwide and is the most common hereditary cause of chronic kidney disease and end-stage renal disease. Most genetically confirmed cases are due to PKD1 variants on chromosome 16, while PKD2 variants on chromosome 4 account for a smaller proportion and are usually associated with milder disease and later progression. A minority of patients have variants in other genes such as GANAB, DNAJB11, ALG8, ALG9, ALG5, and IFT140, which often produce atypical or milder phenotypes.


The disease mechanism involves abnormal function of polycystin proteins, which play essential roles in epithelial cell differentiation, intracellular calcium signaling, and primary ciliary function. Disruption of these pathways leads to cyst formation, epithelial proliferation, and progressive kidney enlargement. Cyst burden and total kidney volume increase over time and are key drivers of disease progression and loss of kidney function.


Clinically, ADPKD is often asymptomatic in the first two to three decades of life. Many patients are diagnosed through family screening or incidental imaging. As cyst burden increases, patients may develop flank pain, hematuria, kidney stones, urinary tract infections, polyuria, nocturia, and hypertension. Gross hematuria commonly results from cyst rupture and is associated with larger kidney size. Proteinuria is usually mild but correlates with more advanced disease.


Hypertension is one of the earliest and most common manifestations of ADPKD and frequently occurs before a decline in kidney function. It is primarily driven by activation of the intrarenal renin–angiotensin–aldosterone system and strongly correlates with cyst burden. Cardiac involvement may include valvular abnormalities such as mitral valve prolapse and aortic regurgitation, contributing to cardiovascular morbidity.


Extrarenal manifestations are common and clinically significant. Liver cysts are the most frequent and increase in prevalence with age, often becoming apparent by early adulthood. Although usually asymptomatic, hepatic cysts can cause pain, infection, bleeding, and biliary obstruction. Intracranial aneurysms occur more frequently in ADPKD than in the general population and carry a risk of rupture, particularly in patients with a family history of aneurysmal bleeding. Other manifestations include pancreatic cysts, colonic diverticula, abdominal and inguinal hernias, and seminal vesicle cysts in men.


Disease progression varies widely. Patients with PKD1 variants generally experience more rapid progression than those with PKD2 variants. Truncating PKD1 mutations are associated with earlier onset of end-stage renal disease. Risk factors for faster progression include male sex, early-onset hypertension, early gross hematuria, proteinuria, and greater total kidney volume. Imaging-based classifications, such as the Mayo Clinic Imaging Classification, use height-adjusted total kidney volume to stratify patients according to risk of progression.


Diagnosis is primarily based on imaging. Renal ultrasound is the most commonly used screening and diagnostic tool due to its availability and lack of radiation. CT and MRI are more sensitive and are often reserved for evaluating complications or measuring total kidney volume. In individuals with a family history, age-specific cyst number criteria are used to establish the diagnosis. Genetic testing may be considered when imaging findings are equivocal or when a definitive diagnosis is required for family planning or living kidney donation.


Management of ADPKD focuses on slowing disease progression, managing complications, and reducing cardiovascular risk. Nonpharmacologic measures include dietary sodium restriction and adequate hydration, particularly in patients with preserved kidney function. Strict blood pressure control, preferably with ACE inhibitors or angiotensin receptor blockers, is central to therapy. Acute complications such as hematuria, infections, and nephrolithiasis are treated supportively and with targeted therapies.


Tolvaptan, a vasopressin V2 receptor antagonist, is the first disease-modifying therapy approved for ADPKD in adults at risk for rapid progression. Clinical trials have demonstrated its ability to slow kidney growth and decline in kidney function, particularly in patients with high cyst burden. Its use requires careful monitoring due to risks of polyuria, dehydration, hypernatremia, and hepatotoxicity. Other investigational and adjunctive therapies are under study, but none have yet shown consistent benefit comparable to tolvaptan.


Patients with ADPKD should be referred early to a nephrologist for longitudinal care and risk stratification. Genetic counseling is recommended for affected individuals and families, especially when considering pregnancy or screening of at-risk relatives. Early recognition, individualized risk assessment, and comprehensive management are essential to improving long-term outcomes in ADPKD.

KembaraXtra-Medicine – Meningococcemia


Meningococcemia is a serious bacterial illness caused by Neisseria meningitidis. It can present in several clinical forms, ranging from mild, self-limited disease to rapidly fatal overwhelming sepsis. Other manifestations include meningococcal meningitis, chronic or occult meningococcemia, septic arthritis, and less commonly localized infections. Transmission occurs through close contact with an infected person or an asymptomatic carrier, with intimate kissing and cigarette smoking recognized as independent risk factors.


The disease is caused by Neisseria meningitidis, a gram-negative diplococcus with multiple serotypes. Although many serotypes exist, most infections are caused by serogroups A, B, C, X, Y, and W135, with serogroup B being the most common in the United States. The organism colonizes the human nasopharynx, the only natural reservoir, and may invade the bloodstream after penetrating nasopharyngeal epithelial cells. Circulating bacteria are normally cleared by the spleen, but meningococci produce a potent endotoxin, lipooligosaccharide, which plays a central role in vascular injury, skin manifestations, adrenal hemorrhage, and circulatory collapse. Carrier rates increase with age, reaching up to 30–40% in young adults, while young children have lower immunity and higher infection risk. Disease incidence peaks in fall and spring and is higher in crowded living conditions such as military barracks and dormitories.


Clinical presentation varies widely. Mild meningococcemia is the most common form and is often preceded by an upper respiratory infection. Patients develop fever, chills, myalgias, arthralgias, and malaise, and the illness may resolve spontaneously over several days. However, this form can progress to meningitis or overwhelming sepsis. Overwhelming meningococcal sepsis occurs in approximately 10% of cases and carries a high mortality rate, with most deaths occurring within the first 48 hours. The onset is abrupt, and early symptoms may appear deceptively mild, including low-grade tachycardia, tachypnea, hypotension, fever, vomiting, headache, rash, and muscle tenderness. Infants may present with lethargy, poor feeding, or a bulging fontanel.


A characteristic rash is a key feature, often beginning as petechiae on the skin, mucous membranes, or conjunctivae, and progressing to purpura and ecchymoses. In severe cases, the rash may coalesce and become necrotic, leading to purpura fulminans. Rapid deterioration may follow, with hypotension, shock, metabolic acidosis, acute respiratory distress syndrome, and disseminated intravascular coagulation. Meningitis may or may not be present. A particularly severe complication is Waterhouse–Friderichsen syndrome, marked by bilateral adrenal hemorrhage, vasomotor collapse, and acute renal failure due to prolonged hypotension.


Chronic meningococcemia is uncommon and presents as a more indolent illness over weeks to months. Patients are often well appearing but experience recurrent fevers, chills, arthralgias, migratory polyarthritis, intermittent painful rashes on the extremities, and sometimes splenomegaly. Meningococcal meningitis presents with headache, fever, neck stiffness, altered mental status, lethargy, or obtundation. Septic arthritis may occur during active bacteremia and typically involves multiple joints with severe pain, swelling, effusion, and restricted movement. Less common manifestations include conjunctivitis, sinusitis, pneumonia, urethritis, salpingitis, prostatitis, myocarditis, and pericarditis.


Diagnosis is primarily clinical and should be suspected in any patient with fever, rash, and rapid clinical deterioration. Importantly, diagnostic evaluation must never delay resuscitation or antibiotic administration. Gram stain and cultures may be obtained from blood, cerebrospinal fluid, joint aspirates, sputum, urine, or scrapings of petechial or papular lesions, which may reveal intracellular or extracellular gram-negative diplococci. Laboratory findings may include leukocytosis early in disease, followed by leukopenia in severe cases, thrombocytopenia in association with purpura or DIC, metabolic acidosis, renal dysfunction, and abnormal coagulation parameters. Polymerase chain reaction testing is particularly useful when antibiotics have already been administered.


Management requires immediate stabilization with strict attention to airway, breathing, and circulation. Droplet precautions should be instituted, and public health authorities notified. Aggressive fluid resuscitation is essential for hypotension, with vasopressors such as dopamine, norepinephrine, or epinephrine if shock persists. Early endotracheal intubation is indicated for severe hypoxia, acidosis, or altered mental status. Empiric intravenous antibiotics must be started promptly, typically with a third-generation cephalosporin, and later tailored once the diagnosis is confirmed. Penicillin remains an option for proven susceptible infections, while chloramphenicol may be used in penicillin-allergic patients.


Supportive care includes management of metabolic acidosis, monitoring of urine output, treatment of DIC with blood products as indicated, and consideration of corticosteroids in select cases, particularly with adrenal involvement. Surgical intervention, including debridement or amputation, may be required for necrotic tissue in severe disease.


All patients with meningococcemia require hospital admission, with intensive care indicated for those with sepsis or shock. Close contacts must receive prompt postexposure prophylaxis, ideally within 24 hours, using agents such as rifampin, ciprofloxacin, or ceftriaxone. Vaccination is recommended for specific high-risk groups and as part of routine adolescent immunization programs.


Key clinical pearls include maintaining a high index of suspicion, notifying public health authorities immediately, and never delaying antibiotic therapy for diagnostic testing. Rapid progression, early shock, and rash should always prompt consideration of meningococcemia, as early treatment is critical to survival.